Mayo Clinic
Rochester, Minnesota, 55905, United States
Location status: Recruiting
NCT Number: NCT07806695
The purpose of this research is to understand how the function of the human pancreas changes during and after pregnancy.
Interested in participating?
Request Info20 year–40 year
Female
Interventional
Phase 1
Rochester, Minnesota, 55905, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exendin 9-39 will be administered during one postpartum study day as an intravenous infusion at 300 pmol/kg/min for 4 hours, beginning 60 minutes before the graded glucose infusion and continuing through the end of the 180-minute glucose infusion study period
Time frame: During pregnancy at approximately 26 to 32 weeks gestation and during the postpartum period at approximately 6 weeks to 3 months after delivery.
The change in glucose concentration necessary to suppress glucagon secretion rate by 50%. A measurement of α-cell function.
Time frame: During pregnancy at approximately 26 to 32 weeks gestation and during the postpartum period at approximately 6 weeks to 3 months after delivery.
The amount of glucagon produced over time expressed as pmol/min. A measurement of α-cell function.
Time frame: During pregnancy at approximately 26 to 32 weeks gestation and during the postpartum period at approximately 6 weeks to 3 months after delivery.
This measurement quantifies the change in insulin secretion in response to rising glucose concentrations. it is a surrogate of β-cell function. Insulin secretion rate will be calculated from C-peptide concentrations using nonparametric deconvolution and population-based measures of C-peptide kinetics.
Time frame: During pregnancy at approximately 26 to 32 weeks gestation and during the postpartum period at approximately 6 weeks to 3 months after delivery.
This index quantifies the relationship between fasting glucose and fasting insulin secretion rate. This will allow us to assess and quantify fasting β-cell function.
Contact information is provided by the study sponsor or research team.
Amy Zipse
CONTACT
Jeanette Laugen
CONTACT
Mayo Clinic
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07802262
Behavior, Diabetes Mellitus
Conway, Arkansas, United States
View Trial DetailsNCT05348863
Diabetes Mellitus, Diabetes, Gestational
Linköping, Sweden
View Trial DetailsNCT04621396
Diabetes Mellitus, Diabetes Mellitus, Type 2
Winnipeg, Manitoba, Canada
View Trial DetailsNCT07158970
Diabetes Mellitus, Diabetes, Gestational
H̱olon, Central District, Israel
View Trial Details